39TH GENERAL ASSEMBLY OF ERIC MEMBERS AT THE 57TH ASH ANNUAL MEETING AND EXPOSITION

6 DECEMBER 2015, ORLANDO, FLORIDA (UNITED STATES OF AMERICA)

  • Agenda
  • General Information (P.Ghia)
  • Minimum Data Set Project (C. Moreno / A. Hadzidimitriou)
  • Expert Forum for NGS Diagnostics in Lymphoid Malignancies – A New Joint ERIC/EHA/EAHP Working Group (R. Rosenquist)

1ST ERIC WORKSHOP ON TP53 ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA

1-3 OCTOBER 2015, MASARYK UNIVERSITY CAMPUS, BRNO (CZECH REPUBLIC)

  • Agenda
  • Introduction (P. Ghia)
  • TP53 mutational analysis – methods and approaches (E. Tausch / J. Malčíková / F. Barran Marszak)
  • European experiences with NGS approaches in CLL (R. Rosenquist)
  • Data interpretation and reporting / How to report results to the clinicians (R. Rosenquist)
  • TP53 mutations are early events in CLL (F. Barran Marszak)
  • TP53 Sequencing: Technical Considerations (A. Jethwa)
  • P53 in health and disease (P. Muller)
  • TP53 Abnormalities in CLL – therapeutic impliactions (M. Doubek)
  • The TP53 UMD Mutation Database Updates and Benefits (T. Soussi)
  • Prognostication in CLL: Present and future (G. Gaidano)
  • P53 function tests in relation to P53 gene aberrations (A. Kater)
  • More info

38TH GENERAL ASSEMBLY OF ERIC MEMBERS AT THE 2OTH CONGRESS OF EHA

11 JUNE 2015, REED MESSE, VIENNA, (AUSTRIA)

  • Agenda
  • General Information (P. Ghia)
  • Launch of TP53 Network (P. Ghia)
  • TP53 workshop (S. Pospíšilová / J. Malčíková)
  • New Round of the TP53 Internal Certification Project (E. Tausch)
  • Bendamustine + Rituximab (BR) Project (A. Cuneo)
  • Flow Cytometric Criteria for CLL Diagnosis: Do we need them (A. Rawstron / D. Oscier )
  • Gene Panel Project (R. Rosenquist)
  • Session 2. ERIC symposium / EHA scientific working group session (Chairperson: Federico Caligaris-Cappio (Milan, Italy)

37TH GENERAL MEETING OF ERIC MEMBERS AT THE 12TH ANNUAL SYMPOSIUM OF THE ELN

3 FEBRUARY 2015, CONGRESS CENTRE ROSENGARTEN, MANNHEIM, (GERMANY)

  • Agenda
  • Introduction, membership update and ERIC roadmap
  • Presentation of a potential TP53 network (P. Ghia)
  • Update on TP53 analysis accreditation project (S. Stilgenbauer / S. Pospíšilová)
  • Accreditation of Ig sequence analysis (A. Hadzidimitriou)
  • Targeted next‐generation sequencing of clinically relevant genes in CLL (R. Rosenquist / K. Stamatopoulos )
  • MRD and NGS (A. Rawstron / P. Ghia)
  • A Phase II trial to study the value of allogeneic stem cell transplantation in the era of ibrutinib
    therapy in high risk CLL (M. van Gelder / A. Kater)